+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Pegvisomant"

Global Acromegaly Treatment Market by Disease Type (Ectopic Acromegaly, Pseudo Acromegaly), Drug Class (Bromocriptine Mesylate (Parlodel), Dopamine Agonists, Growth Hormone Receptor Antagonist), Distribution Channel, End-User - Forecast 2024-2030 - Product Thumbnail Image

Global Acromegaly Treatment Market by Disease Type (Ectopic Acromegaly, Pseudo Acromegaly), Drug Class (Bromocriptine Mesylate (Parlodel), Dopamine Agonists, Growth Hormone Receptor Antagonist), Distribution Channel, End-User - Forecast 2024-2030

  • Report
  • March 2024
  • 194 Pages
  • Global
From
Acromegaly - Market Insight, Epidemiology And Market Forecast - 2032 - Product Thumbnail Image

Acromegaly - Market Insight, Epidemiology And Market Forecast - 2032

  • Report
  • August 2023
  • 147 Pages
  • Global
From
Acromegaly and Gigantism - Global Drug Forecast and Market Analysis to 2029 - Product Thumbnail Image

Acromegaly and Gigantism - Global Drug Forecast and Market Analysis to 2029

  • Report
  • November 2020
  • 225 Pages
  • Global
From
Global Amyloidosis Treatment Market (2023-2028) Competitive Analysis, Impact of COVID-19, Impact of Economic Slowdown & Impending Recession, Ansoff Analysis - Product Thumbnail Image

Global Amyloidosis Treatment Market (2023-2028) Competitive Analysis, Impact of COVID-19, Impact of Economic Slowdown & Impending Recession, Ansoff Analysis

  • Report
  • February 2024
  • 173 Pages
  • Global
From
  • 4 Results (Page 1 of 1)
Loading Indicator

Pegvisomant is a drug used to treat endocrine and metabolic disorders. It is a recombinant form of human growth hormone, and is used to treat acromegaly, a condition caused by excessive growth hormone production. Pegvisomant works by blocking the action of growth hormone, thereby reducing the symptoms of acromegaly. It is administered as a subcutaneous injection, and is typically taken once a day. Pegvisomant is a relatively new drug, and is still in the early stages of development. It is currently approved for use in the United States, Europe, and other countries. The drug is marketed by several pharmaceutical companies, including Pfizer, Novartis, and Ipsen. Pegvisomant is a promising treatment for endocrine and metabolic disorders, and is expected to become increasingly popular in the coming years. It is a safe and effective treatment for acromegaly, and is well-tolerated by patients. Show Less Read more